Adverse Reactions and Drug Interactions with Radiopharmaceuticals

Drug Safety

Volumn 8, Issue 4, 1993, Pages 280-294

  Sampson, Charles B ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN TC 99M; CIMETIDINE; CORTISONE; CYTOTOXIC AGENT; DIETHYLSTILBESTROL; DIGITALIS; ENZYME INDUCING AGENT; ETIDRONIC ACID; GALLIUM CITRATE GA 67; GONADOTROPIN; HALOTHANE; IRON; MEDRONIC ACID; NIFEDIPINE; OPIATE AGONIST; PARACETAMOL; PENTETIC ACID; PHENOTHIAZINE DERIVATIVE; PYROPHOSPHATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; TETRACYCLINE; UNINDEXED DRUG;

ADVERSE DRUG REACTION; ANAPHYLAXIS; BRONCHOSPASM; COLLOID; DELAYED HYPERSENSITIVITY; DERMOGRAPHISM; DIAPHORESIS; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INTERACTION; ERYTHEMA; FAINTNESS; FLUSHING; GYNECOMASTIA; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; LIVER TOXICITY; MALAISE; NAUSEA; PALLOR; RESPIRATORY FAILURE; REVIEW; SHOCK; VOMITING;

ANIMAL; DRUG INTERACTIONS; HUMAN; ORGANOTECHNETIUM COMPOUNDS; RADIOCHEMISTRY; RADIOISOTOPES;

EID: 0027522542     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199308040-00003     Document Type: Review

References (64)

1. Sulfur colloid flocculation due to acid leached aluminium
2. Gallium-67 citrate in gynaecomastia
3. Effect of glucocorticoids on sensitivity of Tc-99m phosphonate bone imaging for detecting bone trauma
4. Adverse reactions to radiopharmaceuticals
5. A study of renal biopsies of light electron and immunofluorescence microscopy
6. Lung uptake of Tc-99m sulphur colloid in patients exhibiting presence of aluminium in plasma
7. Altered biodistribution of Gallium-67 in a patient with aluminium toxicity treated with desferrioxamine
8. Myocardial imaging with Tc-99m pyrophosphate in patients on adriamycin treatment for neoplasia
9. Renal graft evaluation with pertechnetate and I-131 Hippuran: a comparative clinical study
10. Validation and characterisation of adverse reactions to radiopharmaceuticals
11. Adverse reactions to radiopharmaceuticals
12. Idiopathic pulmonary fibrosis; clinical, histologic, radiographic and biochemical aspects
13. Drug induced gallium uptake in the breasts
14. PYP Maalox localisation in liver and spleen
15. European system for reporting of adverse reactions and drug defects: ninth report
16. Hepatobiliary imaging; general considerations
17. Diffuse hepatic uptake of technetium-99m methylene diphosphonate in a patient receiving high dose methotrexate
18. Effect of injection technique on the stability of radiopharmaceuticals
19. Factors which influence the radioactive iodine thyroidal uptake test
20. The role of pharmacologie manipulation in adrenal cortical scintigraphy
21. Gallium-67 citrate imaging: chloroquine overdosage
22. The tissue distribution of gallium radionuclides
23. Cardiac chamber imaging: a comparison of red blood cells labelled with Tc-99m in-vitro and in-vivo
24. Iatrogenic alterations in the biodistribution of radiotracers as a result of drug therapy
25. Gallium mechanisms
26. Side effects associated with the use of radiopharmaceuticals
27. Adverse reactions and untoward events associated with radiopharmaceuticals
28. Adverse reactions and untoward events associated with the use of radiopharmaceuticals
29. Adverse reactions to radiopharmaceuticals, United Kingdom 1977–1983
30. Hepatic tumours in possible relationship to oral contraceptives
31. Pharmacologie alterations in Tc-99m binding by red blood cells: concise communication
32. Iatrogenic alterations in radionuclide biodistribution
33. Delayed renal localisation of Gallium-67: concise communication
34. Intense concentration of Tc-99m pyrophosphate in the kidneys of children treated with chemotherapeutic drugs for malignant disease
35. Low iodine diet in I-131 ablation thyroid remnants
36. Accumulation of Tc-99m diphosphonate at sites of intramuscular iron therapy
37. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumours
38. Failure in labelling of red cells with Tc-99m: interactions between intravenous cannulae and stannous pyrophosphate
39. Clearance of aluminium by haemodialysis: effect of desferrioxamine
40. Altered biodistribution of Ga-67 by intramuscular gold salts
41. Mechanism of I-131 iodobenzylguanidine accumulation in the salivary glands
42. Pulmonary vascular disease in ex-heroin users
43. Effect of heparin and acid-citrate-dextrose on labelling efficiency of Tc-99m labelled RBCs
44. Tc-99m pyrophosphate uptake in drug induced gynaecomastia
45. Nicotinic acid: a cause of failed HIDA scanning
46. Patient medication as a possible cause of unexpected biodistribution of radiopharmaceutical: a regional survey 1981–1991 and a simple algorithm to predict drug/radiopharmaceutical interaction
47. Syringe extractables: effect on radiopharmaceutical
48. Simultaneous treatment of toxic goitre with I-131 and anti-thyroid drugs in a prospective study
49. Hyperprolactinaemia as a cause of Gallium-67 uptake in the breasts
50. Suppression of thyroid radioiodine uptake by various doses of stable iodine
51. Erythromycin hepatotoxicity: a rare case of a false positive technetium DISIDA study
52. Decreased red cell tagging in patients who had received iodinated contrast media
53. Complications after intrathecal administration of Tc-99m DTPA
54. Altered biodistribution of Tc-99m pertechnetate in iatrogenic hyperaluminaemia
55. Steroid induced suppression of gallium uptake tumours of the central nervous system
56. Relative stability of In-111 and Ga-67 desferrioxamine and human transferrin complexes
57. Imaging the primate adrenal medulla with I-123 and I-131 metaiodobenzylguanidine
58. Adverse reactions to radiopharmaceuticals: a preliminary survey in the United Kingdom, 1977–1983
59. Hepatotoxicity from large doses of nicotinamide
60. Tc-99m DMSA renal uptake influence of biochemistry and physiological factors
61. Effect of certain drugs used in the treatment of cardiovascular disease on the in-vitro labelling of red blood cells with Tc-99m